Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Consensus PT from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) has been given an average recommendation of “Buy” by the six research firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock […]

Leave a Reply

Your email address will not be published.

Previous post McDonald’s Co. (NYSE:MCD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Next post Insider Selling: Wabash National Co. (NYSE:WNC) SVP Sells $25,785.00 in Stock